Some keep claiming that the OA market is 10 times the RA market. Are you suggesting that the sales value potential for iPPS for OA is 10 times the size of Humira RA. If so, that is rather misleading. A years supply of Humira in the US costs around $84,000. A course of iPPS, which which probably would not be repeated for 12 months, we are suggesting will cost (ball park) between $3000 and $6000, depending on DMOAD trial results. Still a mightily handsome yearly revenue, but do you see the discrepancy in the revenue expectations for OA.
PAR Price at posting:
$1.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)